journal article·2023-11-10Open access

Advances in Fabrication Technologies for the Development of Next-Generation Cardiovascular Stents

Ankita Das, Shreya Mehrotra, Ashok Kumar

Journal of Functional Biomaterials· Volume 14· Issue 11

Abstract

Coronary artery disease is the most prevalent cardiovascular disease, claiming millions of lives annually around the world. The current treatment includes surgically inserting a tubular construct, called a stent, inside arteries to restore blood flow. However, due to lack of patient-specific design, the commercial products cannot be used with different vessel anatomies. In this review, we have summarized the drawbacks in existing commercial metal stents which face problems of restenosis and inflammatory responses, owing to the development of neointimal hyperplasia. Further, we have highlighted the fabrication of stents using biodegradable polymers, which can circumvent most of the existing limitations. In this regard, we elaborated on the utilization of new fabrication methodologies based on additive manufacturing such as three-dimensional printing to design patient-specific stents. Finally, we have discussed the functionalization of these stent surfaces with suitable bioactive molecules which can prove to enhance their properties in preventing thrombosis and better healing of injured blood vessel lining.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Electrospun Nanofibers in Biomedical Applications · Coronary Interventions and Diagnostics · Cardiac and Coronary Surgery Techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur, Kanpur 208016, UP, India

Centre for Environmental Sciences and Engineering, Indian Institute of Technology Kanpur, Kanpur 208016, UP, India

Centre of Excellence for Orthopaedics and Prosthetics, Gangwal School of Medical Sciences and Technology, Indian Institute of Technology Kanpur, Kanpur 208016, UP, India

The Mehta Family Centre for Engineering in Medicine, Indian Institute of Technology Kanpur, Kanpur 208016, UP, India

Funding

Science and Engineering Research Board (SERB) project

References (100+)

Show source-provided references
1. The Myth of ‘Stable’ coronary artery disease10.1038/s41569-019-0233-y ↗
2. Heart Disease and Stroke Statistics—2019 Update: A Report from the American Heart Association10.1161/CIR.0000000000000659 ↗
3. Coronary Stents: Historical Development, Current Status and Future Directions10.1093/bmb/ldt009 ↗
4. Ueda, P., Gulayin, P., and Danaei, G. (2018). Long-Term Moderately Elevated LDL-Cholesterol and Blood Pressure and Risk of Coronary Heart Disease. PLoS ONE, 13.10.1371/journal.pone.0200017 ↗
5. Chronic Allograft Rejection: A Significant Hurdle to Transplant Success10.4103/2321-3868.121646 ↗
6. Oxidative Stress and Vascular Disease10.1161/01.ATV.0000150649.39934.13 ↗
7. Stable Coronary Artery Disease: Treatment
8. Coronary Artery Bypass Grafting versus Percutaneous Intervention in Coronary Revascularization: A Historical Perspective and Review
9. 2018 ESC/EACTS Guidelines on Myocardial Revascularization10.1093/eurheartj/ehy394 ↗
10. 2023 ESC Guidelines for the Management of Acute Coronary Syndromes10.1093/eurheartj/ehad191 ↗
11. Kaplan, J.A., Cronin, B., and Maus, T.M. (2019). Essentials of Cardiac Anesthesia for Noncardiac Surgery, Elsevier.
12. Long-Term Efficacy of Biodegradable Metal-Polymer Composite Stents after the First and the Second Implantations into Porcine Coronary Arteries10.1021/acsami.0c00971 ↗
13. Coronary Stents: Current Status10.1016/j.jacc.2010.06.007 ↗
14. Pathology of Drug-Eluting Stents in Humans: Delayed Healing and Late Thrombotic Risk10.1016/j.jacc.2006.03.042 ↗
15. Clopidogrel–Drug Interactions10.1016/j.jacc.2010.11.024 ↗
16. The Platinum Chromium Element Stent Platform: From Alloy, to Design, to Clinical Practice10.1007/s12325-010-0022-9 ↗
17. Bio-Resorbable Polymer Stents: A Review of Material Progress and Prospects10.1016/j.progpolymsci.2018.05.002 ↗
18. Coronary Stents: Looking Forward10.1016/j.jacc.2010.06.008 ↗
19. Late Coronary Stent Thrombosis10.1161/CIRCULATIONAHA.106.683995 ↗
20. Response to Letter Regarding Article, “Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization”10.1161/CIRCULATIONAHA.107.727040 ↗
21. Drug-Eluting Stent Thrombosis
22. Emergency Stenting for Acute Occlusion after Coronary Balloon Angioplasty10.1161/01.CIR.78.5.1121 ↗
23. The Development of Bioresorbable Composite Polymeric Implants with High Mechanical Strength10.1038/nmat5016 ↗
24. A Novel Approach to Temporary Stenting: Degradable Cardiovascular Stents Produced from Corrodible Metal-Results 6–18 Months after Implantation into New Zealand White Rabbits10.1136/heart.86.5.563 ↗
25. Strategy of Metal–Polymer Composite Stent to Accelerate Biodegradation of Iron-Based Biomaterials10.1021/acsami.7b15206 ↗
26. Long-Term Biocompatibility of a Corrodible Peripheral Iron Stent in the Porcine Descending Aorta10.1016/j.biomaterials.2006.05.029 ↗
27. Metals and Metal Derivatives in Medicine
28. Bioresorbable Scaffold Technologies10.1253/circj.CJ-10-1135 ↗
29. Biodegradable Stents and Non-Biodegradable Stents
30. A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization10.1056/NEJMoa012843 ↗
31. Six- and Twelve-Month Results from a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions10.1161/01.CIR.0000047700.58683.A1 ↗
32. Drug-Eluting Stent and Coronary Thrombosis10.1161/CIRCULATIONAHA.106.675934 ↗
33. Drug-Eluting Stent Update 200710.1161/CIRCULATIONAHA.106.621342 ↗
34. An Overview of the TAXUS® Express®, Paclitaxel-Eluting Stent Clinical Trial Program10.1111/j.1540-8183.2006.00183.x ↗
35. A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease10.1056/NEJMoa032441 ↗
36. Genous Endothelial Progenitor Cell Capturing Stent vs. the Taxus Liberte Stent in Patients with De Novo Coronary Lesions with a High-Risk of Coronary Restenosis: A Randomized, Single-Centre, Pilot Study10.1093/eurheartj/ehp476 ↗
37. Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice the COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularizat10.1016/j.jcin.2015.03.028 ↗
38. Long-Term Follow-Up of the Randomised Controlled Trial to Evaluate the Safety and Efficacy of the Zotarolimus-Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions: Five Year Outcomes in the ENDEAVOR II Study10.4244/EIJV6I5A95 ↗
39. The “Final” 5-Year Follow-Up from the ENDEAVOR IV Trial Comparing a Zotarolimus-Eluting Stent with a Paclitaxel-Eluting Stent10.1016/j.jcin.2012.12.123 ↗
40. A Randomized Comparison of the Endeavor Zotarolimus-Eluting Stent Versus the TAXUS Paclitaxel-Eluting Stent in De Novo Native Coronary Lesions: 12-Month Outcomes from the ENDEAVOR IV Trial10.1016/j.jacc.2009.08.067 ↗
41. Late-Term Clinical Outcomes with Zotarolimus- and Sirolimus-Eluting Stents: 5-Year Follow-Up of the ENDEAVOR III (a Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System versus the Cypher Sirolimus-Eluting Coro10.1016/j.jcin.2010.12.014 ↗
42. A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute Stents Versus Everolimus-Eluting Xience V Stents in Real-World Patients: The TWENTE Trial10.1016/j.jacc.2012.01.008 ↗
43. 5-Year Results of a Randomized Comparison of XIENCE V Everolimus-Eluting and TAXUS Paclitaxel-Eluting Stents: Final Results From the SPIRIT III Trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patient10.1016/j.jcin.2013.07.009 ↗
44. Randomized Comparison of Everolimus- and Paclitaxel-Eluting Stents: 2-Year Follow-Up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV Trial10.1016/j.jacc.2011.02.022 ↗
45. The SPIRIT V Diabetic Study: A Randomized Clinical Evaluation of the XIENCE V Everolimus-Eluting Stent vs the TAXUS Liberté Paclitaxel-Eluting Stent in Diabetic Patients with De Novo Coronary Artery Lesions10.1016/j.ahj.2012.02.006 ↗
46. Everolimus-Eluting Xience V/Promus Versus Zotarolimus-Eluting Resolute Stents in Patients with Diabetes Mellitus10.1016/j.jcin.2013.12.201 ↗
47. Comparison of Everolimus- and Paclitaxel-Eluting Stents in Patients with Acute and Stable Coronary Syndromes: Pooled Results from the SPIRIT (A Clinical Evaluation of the XIENCE v Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimu10.1016/j.jcin.2011.06.018 ↗
48. Fabrication of Balloon-Expandable Self-Lock Drug-Eluting Polycaprolactone Stents Using Micro-Injection Molding and Spray Coating Techniques10.1007/s10439-010-0075-6 ↗
49. Mechanical Properties, Drug Eluting Characteristics, and in Vivo Performance of a Genipin-Crosslinked Chitosan Polymeric Stent10.1016/j.biomaterials.2009.06.039 ↗
50. Chitosan Glycerophosphate-Based Semirigid Dexamethasone Eluting Biodegradable Stent10.2500/ajra.2009.23.3268 ↗
51. The ABSORB Bioresorbable Vascular Scaffold: An Evolution or Revolution in Interventional Cardiology?
52. Bioresorbable Scaffolds for Percutaneous Coronary Interventions
53. The DESolve Novolimus Bioresorbable Scaffold: From Bench to Bedside10.21037/jtd.2017.07.25 ↗
54. A Next-Generation Bioresorbable Coronary Scaffold System: From Bench to First Clinical Evaluation: 6- and 12-Month Clinical and Multimodality Imaging Results10.1016/j.jcin.2013.07.007 ↗
55. Bioresorbable Scaffolds: Rationale, Current Status, Challenges, and Future10.1093/eurheartj/eht542 ↗
56. DESyne Novolimus-Eluting Coronary Stent Is Superior to Endeavor Zotarolimus-Eluting Coronary Stent at Five-Year Follow-Up: Final Results of the Multicentre EXCELLA II Randomised Controlled Trial10.4244/EIJY15M10_04 ↗
57. Impact of Strut Thickness on Acute Mechanical Performance: A Comparison Study Using Optical Coherence Tomography between DESolve 150 and DESolve 10010.1016/j.ijcard.2017.05.087 ↗
58. Fully Biodegradable Coronary Stents: Progress to Date10.2165/00129784-200808050-00003 ↗
59. 6-Month Clinical and Angiographic Outcomes of a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold: The FANTOM II Study10.1016/j.jcin.2017.07.033 ↗
60. Bioresorbable Scaffolds in the Treatment of Coronary Artery Disease
61. Long-Term Outcomes of Internal Carotid Artery Dissection10.1016/j.jvs.2011.02.059 ↗
62. Indigenous Stents: Examining the Clinical Data on New Technologies10.2217/ica.14.27 ↗
63. Comparative Characterization of Biomechanical Behavior and Healing Profile of a Novel Ultra-High-Molecular-Weight Amorphous Poly-l-Lactic Acid Sirolimus-Eluting Bioresorbable Coronary Scaffold10.1161/CIRCINTERVENTIONS.116.004253 ↗
64. Bioresorbable Vascular Scaffolds—Basic Concepts and Clinical Outcome10.1038/nrcardio.2016.151 ↗
65. Wu, Y., Shen, L., Wang, Q., Ge, L., Xie, J., Hu, X., Sun, A., Qian, J., and Ge, J. (2012). Comparison of Acute Recoil between Bioabsorbable Poly-L-Lactic Acid XINSORB Stent and Metallic Stent in Porcine Model. J. Biomed. Biotechnol., 2012.10.1155/2012/413956 ↗
66. A Head to Head Comparison of XINSORB Bioresorbable Sirolimus-Eluting Scaffold versus Metallic Sirolimus-Eluting Stent: 180 Days Follow-Up in a Porcine Model10.1007/s10554-017-1148-5 ↗
67. Vascular Restoration Therapy and Bioresorbable Vascular Scaffold10.1093/rb/rbu005 ↗
68. Progress in Treatment by Percutaneous Coronary Intervention: The Stent of the Future10.1016/j.recesp.2012.12.009 ↗
69. Novel Fully Bioabsorbable Salicylate-Based Sirolimus-Eluting Stent10.4244/EIJV5IFA10 ↗
70. Tenekecioglu, E., Farooq, V., Bourantas, C.V., Silva, R.C., Onuma, Y., Yilmaz, M., and Serruys, P.W. (2016). Bioresorbable Scaffolds: A New Paradigm in Percutaneous Coronary Intervention. BMC Cardiovasc. Disord., 16.10.1186/s12872-016-0207-5 ↗
71. TCT-546 6-Month Angiographic Results of the Novel MIRAGE Microfiber Sirolimus-Eluting Bioresorbable Vascular Scaffold—A Quantitative Coronary Angiography Analysis from the Prospective, Randomized MIRAGE Clinical Trial10.1016/j.jacc.2015.08.563 ↗
72. Initial and 6-Month Results of Biodegradable Poly-l-Lactic Acid Coronary Stents in Humans10.1161/01.CIR.102.4.399 ↗
73. Long-Term (>10 Years) Clinical Outcomes of First-in-Human Biodegradable Poly-l-Lactic Acid Coronary Stents: Igaki-Tamai Stents10.1161/CIRCULATIONAHA.110.000901 ↗
74. Comparison of a Drug-Free Early Programmed Dismantling PDLLA Bioresorbable Scaffold and a Metallic Stent in a Porcine Coronary Artery Model at 3-Year Follow-Up10.1161/JAHA.117.005693 ↗
75. Head-to-Head Comparison of a Drug-Free Early Programmed Dismantling Polylactic Acid Bioresorbable Scaffold and a Metallic Stent in the Porcine Coronary Artery: Six-Month Angiography and Optical Coherence Tomographic Follow-Up Study10.1161/CIRCINTERVENTIONS.113.000738 ↗
76. Current and Future Perspectives on Drug-Eluting Bioresorbable Coronary Scaffolds10.2217/fca.14.14 ↗
77. Bioresorbable Stents for Pediatric Practice: Where Are We Now?10.2217/ica.15.6 ↗
78. Patterns and Mechanisms of In-Stent Restenosis10.1161/01.CIR.94.6.1247 ↗
79. Safety and Performance of the Second-Generation Drug-Eluting Absorbable Metal Scaffold in Patients with de-Novo Coronary Artery Lesions (BIOSOLVE-II): 6 Month Results of a Prospective, Multicentre, Non-Randomised, First-in-Man Trial10.1016/S0140-6736(15)00447-X ↗
80. Safety and Performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in Patients with De Novo Coronary Lesions: 3-Year Results of the Prospective, Multicentre, First-in-Man BIOSOLVE-I Trial10.4244/EIJ-D-15-00371 ↗
81. A Word of Caution: Early Failure of Magmaris® Bioresorbable Stent after Pulmonary Artery Stenting10.1002/ccd.30487 ↗
82. Gallic Acid and Gallic Acid-Loaded Coating Involved in Selective Regulation of Platelet, Endothelial and Smooth Muscle Cell Fate10.1039/C3RA44217A ↗
83. Very Late Scaffold Thrombosis of Bioresorbable Vascular Scaffold: Systematic Review and a Meta-Analysis10.1016/j.jcin.2016.10.027 ↗
84. Effect of Stent Size on Complications and Recurrent Dysphagia in Patients with Esophageal or Gastric Cardia Cancer10.1016/j.gie.2006.12.018 ↗
85. Determination of Patient-Specific Airway Stent Fit Using Novel 3D Reconstruction Measurement Techniques: A 4-Year Follow-Up of a Patient10.1177/17534666221137999 ↗
86. Alexy, R.D., and Levi, D.S. (2013). Materials and Manufacturing Technologies Available for Production of a Pediatric Bioabsorbable Stent. Biomed. Res. Int., 2013.10.1155/2013/137985 ↗
87. Microfabrication and Nanotechnology in Stent Design10.1002/wnan.123 ↗
88. Image-Guided Tissue Engineering of Anatomically Shaped Implants via MRI and Micro-CT Using Injection Molding10.1089/ten.tea.2007.0186 ↗
89. Biomedical Production of Implants by Additive Electro-Chemical and Physical Processes10.1016/j.cirp.2012.05.005 ↗
90. Synthesis and 3D Printing of Biodegradable Polyurethane Elastomer by a Water-Based Process for Cartilage Tissue Engineering Applications10.1002/adhm.201400018 ↗
91. High Performance Polymer Nanocomposites for Additive Manufacturing Applications10.1016/j.reactfunctpolym.2016.04.010 ↗
92. A Review of Additive Manufacturing10.5402/2012/208760 ↗
93. Optimization of Fused Deposition Modeling Process Parameters: A Review of Current Research and Future Prospects10.1007/s40436-014-0097-7 ↗
94. Biodegradable and Bioactive Porous Scaffold Structures Prepared Using Fused Deposition Modeling10.1002/jbm.b.32863 ↗
95. Konta, A., García, M., and Serrano, D. (2017). Personalised 3D Printed Medicines: Which Techniques and Polymers Are More Successful?. Bioengineering, 4.10.3390/bioengineering4040079 ↗
96. Metallic Architectures from 3D-Printed Powder-Based Liquid Inks10.1002/adfm.201503921 ↗
97. Additive Manufacturing (AM) and Nanotechnology: Promises and Challenges10.1108/RPJ-12-2011-0127 ↗
98. 3D-Printed Multidrug-Eluting Stent from Graphene-Nanoplatelet-Doped Biodegradable Polymer Composite10.1002/adhm.201700008 ↗
99. A Clinically Relevant Large-Animal Model for Evaluation of Tissue-Engineered Cardiac Surgical Patch Materials10.1016/j.carrev.2005.07.006 ↗
100. 3D Printed Self-Expandable Vascular Stents from Biodegradable Shape Memory Polymer10.1002/adv.22091 ↗